【摘要】 目的:检测microRNA-16(miR-16)在多发性骨髓瘤(MM)患者骨髓单个核细胞(BMMNC)中表达水平,分析miR-16表达水平与Durie-Salmon分期法(D-S分期法)和常用肿瘤负荷指标β2微球蛋白(β2-MG)的相关性,探讨miR-16在MM的发生、发展及预后中的意义。方法:收集43例MM患者及20例正常对照的骨髓标本,用D-S分期法对MM患者进行临床分期,行髂穿获取BMMNC,采用实时荧光定量PCR(real-time PCR)的方法检测BMMNC中miR-16表达,同步抽取外周血,检测β2-MG水平。结果:①miR-16在MM中表达水平明显低于正常对照组,复发/难治组MM患者miR-16表达水平明显低于初治组MM患者,差异有统计学意义(P<0.05);②MM患者化疗后miR-16表达水平较化疗前明显升高(P<0.05),其中以化疗有效组升高最为明显(P<0.05),无效/进展组miR-16表达水平化疗前后无明显改变;③miR-16表达水平与患者病程D-S分期和β2-MG水平有相关性)。结论:miR-16低表达在MM的发病中发挥着重要作用,与MM肿瘤细胞的增殖、转移的能力和疾病预后有密切关系;miR-16表达水平与β2-MG、D-S分期呈负相关,可作为判断MM患者预后指标之一。更多还原

【Abstract】 Objective:To explore the expression of microRNA-16(miR-16)in multiple myeloma(MM),and study its correlation with β2-microglobulin and staging of MM by Durie-Salmon classification.Method: The expression levels of miR-16 in bone marrow mono-nuclear cells of MM were examined by Real-time polymerase chain reaction(Real-time PCR),and the correlations between the expression levels of miR-16 and related clinic pathologic features β2-microglobulin,staging of MM by Durie-Salmon classification)were further analyzed.Result:The expression of miR-16 in MM patients was obviously lower than that in normal control(P<0.05).The expression of miR-16 in relapsed/refractory MM patients was obviously lower than that in newly diagnosed MM patients.The expression of miR-16 in MM patients increased after chemical therapy than that before treatment,especially in effective group(P<0.05).There was no statistically significant change in ineffective/progress group after chemical therapy(P>0.05).The expression of miR-16 was associated to staging of MM and β2-microglobulin level.Conclusion:Expression levels of miR-16 in MM patients are significantly lower than that in normal bone marrow,these data indicated that miR-16 may play an important role in the development of MM.Low-regulated expression of miR-16 was associated with β2-microglobulin and staging of MM by Durie-Salmon classification.更多还原